The Next Generation of Investors
Inovio (NASDAQ:INO) is set to open 10% higher this morning after the promising address by CEO & President Dr. Joseph Kim on the H.C Wainwright 22nd Annual Investment Conference. Dr. Kim advised that the initiation of Phase 2 trials for their COVID-19 vaccine INO-4800 is on track to commence later this month.…
Biomerica (NASDAQ:BMRA) is set to release Q2 earnings this Friday, with experts forecasting an expected EPS of -$0.05. This would mark a 37% improvement for Q2 Earnings Year on Year. The medical diagnostic manufacturer has thrived on the opportunity this year to develop a viable COVID-19 test.…
Fluidigm Corporation (NASDAQ: FLDM) just became a bull-market magnet as its COVID-19 saliva kit received FDA approval. Optimism is high in pre-market trading as some bullish investors believe this is news to send FLDM soaring. However, the bears are screaming that a pump and dump is coming at the bell.…
Johnson & Johnson announced this morning that they have entered a “definitive agreement” to acquire Momenta Pharmaceuticals at $52.50 per share. The acquisition has been confirmed as an all-cash transaction, which has been approved “unanimously” by the Board of Directors from both J&J and Momenta.…
CureVac’s (NASDAQ:CVAC) initial public offering in the US markets went incredibly well for investors, posting a 250% gain on its first day of trading. CureVac is a German Biopharma, based in Tübingen who specialises in the development of vaccines for infectious diseases.…
Moderna (NASDAQ: MRNA), alongside Novavax, is running at full speed in the vaccine race. The Trump Administration’s recent agreement with Moderna to order 100 million doses adds to the argument that MRNA is at the front of the pack. While the announcement is a positive catalyst, investors are doubtful that we will see an enormous rally.…
The COVID-19 vaccine industry has seen immense investor backing with popular US listed companies such as Moderna, Pfizer and Vaxart multiplying their pre-COVID value upwards of 500%-1,000%. However, Novavax, Inc. (NASDAQ: NVAX) has surpassed it’s rivals in stock value growth, currently priced at $143.10.…
Binano Genomics (NASDAQ: BNGO) catapulted itself onto the COVID-19 stage this week, which naturally saw investors flood the market. The area that BNGO is targeting is the COVID research field. However, for most investors, the scientific jargon can make the task of understanding the company, let alone investing, extremely difficult.…
Actinium Pharmaceuticals (NYSE:ATNM) has caught the attention of investors as the stock continues its path of strong bullish momentum. ATNM is likely to open at $0.56 according to pre-market movements, marking a 211% gain over the past 2 months. The Bio-Pharma works on the development of commercial therapies for bone marrow transplant and other adoptive cell therapies.…
Moderna (NASDAQ:MRNA)Â alongside the US National Institutes of Health have made a historic breakthrough in the race for a viable COVID-19 vaccine. MRNA’s results showed all 45 patients from the Phase 1 trial saw an induced anti-body production. This anti-body production simply put helps bolster the individuals immune response to the virus.…
Sorrento Therapeutics’ (NASDAQ: SRNE) saying they have a COVID-19 treatment that offers a 100% protection, before conducting trials, was an incredibly bold statement. SRNE’s optimistic announcement not only lit the investment world alight but also pushed them into the legal spotlight.…
Adaptimmune Therapeutics PLC (Nasdaq: ADAP) skyrocketed 128% on Friday. Investors rallied behind ADAP because of their positive phase 1 cancer trial. ADAP’s synovial sarcoma cancer candidate (ADP-A2M4) reported a 50% response rate in patients suffering from lung, head, and neck cancers.…
A cure for cancer is the most desirable statement for scientists and investors alike. However, optimism is often met with disappointment as the task of curing cancer is no easy feat. Despite the difficulty, the scientific world continues to develop drug after drug in an attempt to eradicate the horrific group of diseases.…
Why did the stock rise?
Evofem made headlines after the FDA approved Evofem’s (NASDAQ: EVFM) new birth control gel “Phexxi.” Phexxi is an applicator that women insert before sex to prevent pregnancy. The FDA approved the drug through Phase 3 clinical trial, enrolling tests of 1,330 women.…
The vaccine race involves many runners, with the leaders being Moderna (NASDAQ: MRNA), Inovio (NASDAQ: INO), and Novavax (NASDAQ: NVAX). It feels like many vaccine companies are sprinting as they accelerate through the clinical timeline.
However, the US government raised the stakes on Thursday when they announced a $1.2 billion injection into AstraZene’s untried vaccine.…
Seneca Biopharma (NASDAQ: SNCA) came out of the markets storming 100% higher today at $1.67. The volcanic surge is off the back on no news, leaving investors confused. SNCA forums on Yahoo Finance and Stockwits are flooded with the same question “why is SNCA up”?…
Moderna announced this morning that their interim Phase 1 data for COVID-19 vaccine has shown positive results. The company has been heavily watched by investors and speculators alike – as their vaccine (mRNA-1273) continues to show positive signs. The announcement confirmed the Biomedical Advanced Research and Development Authority (BARDA) are in support of the companies phase 2 and 3 trials, as well as scaling up the manufacturing of the vaccine.…
Novavax (NASDAQ:NVAX) look to surge come market open with pre-market up 13% (at the time of writing). Novavax captured the wallets of investors last week when they received $384 million in vaccine funding from CEPI. This week NVAX is expected to captivate investors with a new all-time-high.…
Trump announced on Friday that the US Food and Drug Administration has cleared the emergency use of Remdesivir as a COVID-19 treatment. Gilead Sciences (NASDAQ:GILD) will play a vital role in producing 1.5 million doses for patients across the US suffering critical complications from COVID-19.…
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area.
Since launching , YIG has published articles relating to commodities (Cobalt) and Tech companies.…